was 4.0 (3.5-5.0) and 4.5 (3.7-5.6) in the newer one. We have introduced more confidence intervals and modified out discussion in the abstract and discussion sections accordingly. The sample size is of lesser importance given that our findings are consistent with all other data in the field -- the merit our study adds is its cohort nature makes it easier to see where risks arise Finally, the authors attribute some of the high SMR to antipsychotic medication. This seems overly simplistic -- many other possible reasons could explain the high SMR (to increasing stigma, lack of family support, untreated comorbid depression). Schizophrenia is a heterogeneous disease, and therefore the potential problems with diagnosis, changes in etiology, and treatment over the 70+ time periods between these two cohorts mean that in my view these data are at most hypothesis generating, but cannot be presented as definitive findings. We have discussed this in detail in the revision.  We offer reasons why medication is the most likely option -- but have made this suggestion more tentative. Two methodological queries -- it is unclear from the text how SMRs were calculated for the newer cohort. Ideally, SMRs for each cause of death for every year by age band should be calculated. The text reads as if the authors took average SMRs for each cause of death over 1994-2010. I don't think this is correct as there have been changes to suicide SMRs over this period, and the limited power of this study would argue